 NEW YORK and VIENNA, Austria, May 26, 2022 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that complete HB-200 Phase 1 results NCT04180215 for single-vector HB-201 and alternating 2-vector HB-202HB-201 in patients with advanced Human Papillomavirus 16-positive HPV16 cancers, including the recommended Phase 2 dose for HB-202HB-201, will be shared in a poster presentation at the 2022 American Society of Clinical Oncology ASCO Annual Meeting, taking place June 3-7, 2022. Data as of March 31, 2022 will be presented on 68 patients, 54 of whom had head and neck squamous cell carcinoma HNSCC. 